Drug intelligence / Profile preview

pfs230d1m-epa + alhydrogel

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Pfs230D1M-EPA + Alhydrogel is a malaria transmission-blocking vaccine candidate consisting of recombinant Plasmodium falciparum surface protein 230 domain 1 (Pfs230D1M) conjugated to Pseudomonas aeruginosa ExoProtein A (EPA) and formulated with Alhydrogel as an adjuvant. The vaccine targets the sexual stage development of P. falciparum parasites, inducing antibodies that prevent malaria transmission from humans to mosquitoes. It works through a complement-dependent mechanism, where antibodies against Pfs230 block parasite development in the mosquito midgut.

Other names: Pfs230D1-EPA/Alhydrogel

Targets

Pfs230D1 (Pfs230 domain 1)

Beyond the preview

Go deeper on pfs230d1m-epa + alhydrogel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pfs230d1m-epa + alhydrogel.

Explore the full profile